title: Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study.
abstract: BACKGROUND
  Evidence indicates that systolic blood pressure (SBP) reduction may reduce hematoma expansion in patients with intracerebral hemorrhage (ICH) who are initially seen with acute hypertensive response.
  
  
  OBJECTIVE
  To explore the relationship between different variables of SBP reduction and hematoma expansion, perihematomal edema, and 3-month outcome among patients with ICH.
  
  
  METHODS
  Post hoc analysis of a traditional phase 1 dose-escalation multicenter prospective study.
  
  
  METHODS
  Emergency departments and intensive care units.
  
  
  METHODS
  Patients having ICH with an elevated SBP of at least 170 mm Hg who were seen within 6 hours of symptom onset.
  
  
  METHODS
  Systolic blood pressure reduction using intravenous nicardipine hydrochloride targeting 3 tiers of sequentially escalating SBP reduction goals (170-199, 140-169, or 110-139 mm Hg).
  
  
  METHODS
  We evaluated the effect of SBP reduction (relative to initial SBP) on the following: hematoma expansion (defined as an increased intraparenchymal hemorrhage volume >33% on 24-hour vs baseline computed tomographic [CT] images), higher perihematomal edema ratio (defined as a >40% increased ratio of edema volume to hematoma volume on 24-hour vs baseline CT images), and poor 3-month outcome (defined as a modified Rankin scale score of 4-6).
  
  
  RESULTS
  Sixty patients (mean [SD] age, 62.0 [15.1] years; 34 men) were recruited (18, 20, and 22 patients in each of the 3 SBP reduction goal tiers). The median area under the curve (AUC) (calculated as the area between the hourly SBP measurements over 24 hours and the baseline SBP) was 1360 (minimum, 3643; maximum, 45) U. Comparing patients having less vs more aggressive SBP reduction based on 24-hour AUC analysis, frequencies were 32% vs 17% for hematoma expansion, 61% vs 40% for higher perihematomal edema ratio, and 46% vs 38% for poor 3-month outcome (P > .05 for all). The median SBP reductions were 54 mm Hg at 6 hours and 62 mm Hg at 6 hours from treatment initiation. Comparing patients having equal to or less vs more than the median SBP reduction at 2 hours, frequencies were 21% vs 31% for hematoma expansion, 42% vs 57% for higher perihematomal edema ratio, and 35% vs 48% for poor 3-month outcome (P > .05 for all).
  
  
  CONCLUSIONS
  We found no significant relationship between SBP reduction and any of the outcomes measured herein; however, the Antihypertensive Treatment of Acute Cerebral Hemorrhage study was primarily a safety study and was not powered for such end points. The consistent favorable direction of these associations supports further studies with an adequately powered randomized controlled design to evaluate the efficacy of aggressive pharmacologic SBP reduction.
authors.affiliation: Zeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis, MN 55455, USA. qureshi@umn.edu
authors.forename: Adnan I
authors.initials: AI
authors.lastname: Qureshi
authors.forename: Yuko Y
authors.initials: YY
authors.lastname: Palesch
authors.forename: Reneé
authors.initials: R
authors.lastname: Martin
authors.forename: Jill
authors.initials: J
authors.lastname: Novitzke
authors.forename: Salvador
authors.initials: S
authors.lastname: Cruz-Flores
authors.forename: As'ad
authors.initials: A
authors.lastname: Ehtisham
authors.forename: Mustapha A
authors.initials: MA
authors.lastname: Ezzeddine
authors.forename: Joshua N
authors.initials: JN
authors.lastname: Goldstein
authors.forename: Haitham M
authors.initials: HM
authors.lastname: Hussein
authors.forename: M Fareed K
authors.initials: MF
authors.lastname: Suri
authors.forename: Nauman
authors.initials: N
authors.lastname: Tariq
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D001921:Brain / Q000098:blood supply / Q000378:metabolism / Q000473:pathology; D001929:Brain Edema / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D002536:Cerebral Arteries / Q000187:drug effects / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004632:Emergency Medical Services / Q000379:methods / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D020299:Intracranial Hemorrhage, Hypertensive / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000008:administration & dosage / Q000009:adverse effects; D017063:Outcome Assessment, Health Care; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D009529:Nicardipine
references.citation: Stroke. 1997 Dec;28(12):2370-5
references.pmid: 9412616
references.citation: Neurology. 2006 Apr 25;66(8):1175-81
references.pmid: 16636233
references.citation: Am J Emerg Med. 2007 Jan;25(1):32-8
references.pmid: 17157679
references.citation: Stroke. 2002 Sep;33(9):2243-6
references.pmid: 12215594
references.citation: Neurology. 1999 Dec 10;53(9):2176-9
references.pmid: 10599801
references.citation: Am J Physiol. 1991 Jan;260(1 Pt 2):R172-8
references.pmid: 1992818
references.citation: Stroke. 2002 Nov;33(11):2636-41
references.pmid: 12411654
references.citation: J Neurosurg. 1990 Feb;72(2):195-9
references.pmid: 2295917
references.citation: Stroke. 1997 Jan;28(1):1-5
references.pmid: 8996478
references.citation: Neurocrit Care. 2007;6(1):56-66
references.pmid: 17356194
references.citation: Stroke. 2006 Aug;37(8):2061-5
references.pmid: 16794216
references.citation: AJNR Am J Neuroradiol. 2006 Mar;27(3):666-70
references.pmid: 16552014
references.citation: Stroke. 1999 Apr;30(4):905-15
references.pmid: 10187901
references.citation: Circulation. 2008 Jul 8;118(2):176-87
references.pmid: 18606927
references.citation: Neurosurg Clin N Am. 2002 Jul;13(3):355-70
references.pmid: 12486925
references.citation: Stroke. 1995 Jan;26(1):21-4
references.pmid: 7839391
references.citation: Crit Care Med. 2000 May;28(5):1556-64
references.pmid: 10834711
references.citation: Crit Care Med. 1999 May;27(5):965-71
references.pmid: 10362421
references.citation: Stroke. 2002 Nov;33(11):2631-5
references.pmid: 12411653
references.citation: Lancet. 2009 May 9;373(9675):1632-44
references.pmid: 19427958
references.citation: N Engl J Med. 2005 Feb 24;352(8):777-85
references.pmid: 15728810
references.citation: Neurology. 1999 Jan 15;52(2):266-72
references.pmid: 9932942
references.citation: J Hypertens. 2003 Nov;21(11):2167-73
references.pmid: 14597861
references.citation: Stroke. 2007 Mar;38(3):1072-5
references.pmid: 17290026
references.citation: Stroke. 1991 Oct;22(10):1242-4
references.pmid: 1833860
references.citation: Crit Care Med. 2006 Jul;34(7):1975-80
references.pmid: 16641615
references.citation: Lancet Neurol. 2008 May;7(5):391-9
references.pmid: 18396107
references.citation: Neurology. 1989 Nov;39(11):1509-14
references.pmid: 2812332
references.citation: Neurology. 2001 Jul 10;57(1):18-24
references.pmid: 11445622
references.citation: Stroke. 1988 May;19(5):604-7
references.pmid: 3363593
references.citation: Neurol Med Chir (Tokyo). 2001 Jun;41(6):300-4; discussion 304-5
references.pmid: 11458742
references.citation: J Neurosurg Anesthesiol. 2002 Jan;14(1):22-30
references.pmid: 11773819
references.citation: J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):378-80
references.pmid: 16484648
references.citation: Crit Care Med. 2010 Feb;38(2):637-48
references.pmid: 19770736